Viral enzymes and entry proteins

Viral enzymes and entry proteins are a broad class of viral-encoded molecules essential for the viral life cycle, including attachment, entry, replication, and maturation. Viral enzymes such as polymerases, proteases, and integrases are responsible for synthesizing and processing viral genetic material and proteins, making them critical targets for drugs like remdesivir and ritonavir (1, 2). Entry proteins, typically surface glycoproteins or spike proteins, facilitate the virus's ability to bind to and fuse with host cell membranes, a process targeted by inhibitors like maraviroc and enfuvirtide (3). Because these proteins are often unique to the virus, they provide a basis for selective antiviral activity with reduced host toxicity (4). However, the rapid evolution of viruses frequently leads to mutations in these targets, resulting in drug resistance and necessitating the development of combination therapies (5). (1) NIH NIAID. "Antiviral Drug Development." (2) De Clercq, E., & Li, G. (2016). "Proximal and distal antiviral drug targets." Nature Reviews Drug Discovery. (3) Marsh, M., & Helenius, A. (2006). "Virus entry: open sesame." Cell. (4) FDA. "Antiviral Drugs Advisory Committee." (5) Strasfeld, L., & Chou, S. (2010). "Antiviral Drug Resistance: Mechanisms and Clinical Implications." Infectious Disease Clinics of North America.

Other names

Viral proteinsViral replication proteinsViral entry factorsAntiviral drug targets

Antiviral drugs target viral enzymes and entry proteins through several mechanisms: polymerase inhibitors (e.g., nucleoside analogs) terminate viral genome replication; protease inhibitors prevent the cleavage of viral polyproteins into functional units; integrase inhibitors block the insertion of viral DNA into the host genome; and entry/fusion inhibitors prevent the virus from attaching to or entering the host cell (1, 2).